Healthcare Global Enterprises Limited

rs,

Mumbai - 400051, Maharashtra, India BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India Dear Sir/Madam, Subject : Investor Presenta

rs1

Largest Pan-India Oncology Hospital Chain 2 22 4* 6 Center of Excellence (CoE) Cancer Care Centers1 Multi-specialty hospitals Day care centers Jaipur Ahmedabad Indore Ranchi Rajkot Bhavnagar B

55%

ngole Suchirayu Hubli Shimoga Vijaywada Kenya Bangalore LARGEST GEOGRAPHICAL REACH… 10 19 ~55% Number of states covered5 Number of cities covered5 Addressable market3 (population) 25 16/1

14%

G ONCOLOGY MARKET IN INDIA INDIA IS A SIGNIFICANTLY UNDER-COVERED CANCER INDUSTRY INRbn CAGR 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019

12%

NDER-COVERED CANCER INDUSTRY INRbn CAGR 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019 Population growth Cancer incidences Relapse driven

3%

COVERED CANCER INDUSTRY INRbn CAGR 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019 Population growth Cancer incidences Relapse driven Af

1%

R INDUSTRY INRbn CAGR 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019 Population growth Cancer incidences Relapse driven Affordability R

97%

CAGR 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019 Population growth Cancer incidences Relapse driven Affordability Realization 2024

89%

R 13-14% Population coverage by cancer registries1 CAGR 12% 3% 263 3% 1% 151 1% 3% 97% 89% 2019 Population growth Cancer incidences Relapse driven Affordability Realization 2024 2030E

41%

2019 Population growth Cancer incidences Relapse driven Affordability Realization 2024 2030E 41% 10% 1 in every 9 people in India to potentially suffer from cancer by 2025 Sources: Globacan 201

10%

Population growth Cancer incidences Relapse driven Affordability Realization 2024 2030E 41% 10% 1 in every 9 people in India to potentially suffer from cancer by 2025 Sources: Globacan 2018, IC

81%

key problems LOW EARLY-STAGE DIAGNOSIS IN INDIA… … LEADING TO HIGH MORTALITY TO INCIDENCE RATIO 81% 71% 73% 29% 31% 30% 19% 8% 31% 26% 25% 15% 51% 52% 56% 17% 22% 28% 33% 23% 88%

“Although the Company believes that such forward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met.”

“c o m 24 Q4 & FY25 FINANCIAL & OPERATIONAL HIGHLIGHTS SUBASENI LENKA, CANCER WINNER I am eternally thankful to Dr.”

“c o m 31 HCG – FY25 Operational Metrics # T O T A L A O R ( % ) E S T A B L I S H E D C E N T E R S A O R ( % ) E M E R G I N G C E N T E R S A O R ^ * ( % ) E s t a b l i s h e d C e n t e r s P r e I n d A S R O C E ( % ) 65.7% 6 4 .”

“1 % i n F Y 2 4 7 5 0 b p s Operational beds increased from 1,943 in FY24 to 2,140 in FY25.”

“c o m 33 Milann – Implementing Strategic Initiatives Particulars Q4FY25 Q4FY24 Growth Y-o-Y FY25 FY24 Growth Y-o-Y New Registrations 1,019 958 6% 4,334 4,446 -2.5% B E N G A L U R U ( 5 C e n t e r s ) Shivananda Indiranagar IVF Cycles 256 375 -32% 1,289 1,635 -21% Whitefield Sarjapur JP Nagar Revenues (Rs.”

“) HCG CENTERS FY25 FY24 Established Centers Emerging Centers TOTAL CAPEX 1,976 80 2,056 1,836 41 1,876 O N G O I N G C A P E X ( R s .”

“No 1 2 Particulars Capex incurred till 31 st March 2025 Total Planned Capex Expected Operational period North Bangalore Whitefield (Extension of Bangalore - COE) 185 137 900 290 H2 FY26 H2 FY26 1.”

“c o m Q4 & FY25 Consolidated Profit & Loss Account Profit and Loss (in Rs.”

Subject

1

Subject

Investor Presentation Stock Code : BSE – 539787, NSE – HCG We wish to inform you that the Board of Directors of the Company, at their meeting held on Saturday, May 24, 2025, inter alia, has considered and approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2025 (“Financial Results”). We enclose herewith the Presentation on the Financial Results of the Company for the quarter and year ended March 31, 2025. Request you to take this on record. Thanking you, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary & Compliance Officer Encl: a/a. HealthCare Global Enterprises Limited HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489 HEALTHCARE GLOBAL ENTERPRISES LIMITED I NV ESTOR P RESENTATI ON May 2025 SAFE HARBOR This presentation and its contents are confidential and are not for release,